DaVita (NYSE: DVA) reported Q3 EPS of $0.56, $0.31 worse than the analyst estimate of $0.87. Revenue for the quarter came in at $2.85 billion versus the consensus estimate of $2.93 billion.

Outlook

• We now expect our Kidney Care adjusted consolidated operating income for 2018 to be in the range of $1.5 billion to $1.525 billion. Our previous guidance for our Kidney Care adjusted consolidated operating income for 2018 was in the range of $1.5 billion to $1.6 billion.
• We still expect our operating cash flow from continuing operations for 2018 to be in the range of $1.4 billion to $1.6 billion.
• We now expect our 2018 effective income tax rate on income from continuing operations attributable to DaVita Inc. to be approximately 30.5% to 31.5%.Our previous guidance for our 2018 effective income tax rate on income from continuing operations attributable to DaVita Inc. was approximately 28.5% to 29.5%.

GUIDANCE:

For earnings history and earnings-related data on DaVita (DVA) click here.